These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 39106541

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial.
    Meuth SG, Henze T, Essner U, Trompke C, Vila Silván C.
    Int J Neurosci; 2020 Dec; 130(12):1199-1205. PubMed ID: 32065006
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Riva N, Mora G, Sorarù G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G, CANALS Study Group.
    Lancet Neurol; 2019 Feb; 18(2):155-164. PubMed ID: 30554828
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain.
    Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Kornyeyeva E, Fallon MT.
    J Pain Symptom Manage; 2018 Feb; 55(2):179-188.e1. PubMed ID: 28923526
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The influence of physiotherapy intervention on patients with multiple sclerosis-related spasticity treated with nabiximols (THC:CBD oromucosal spray).
    Grimaldi AE, De Giglio L, Haggiag S, Bianco A, Cortese A, Crisafulli SG, Monteleone F, Marfia G, Prosperini L, Galgani S, Mirabella M, Centonze D, Pozzilli C, Castelli L.
    PLoS One; 2019 Feb; 14(7):e0219670. PubMed ID: 31361750
    [Abstract] [Full Text] [Related]

  • 11. Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice.
    Flachenecker P, Henze T, Zettl UK.
    Eur Neurol; 2014 Feb; 72(1-2):95-102. PubMed ID: 24943098
    [Abstract] [Full Text] [Related]

  • 12. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience.
    D'hooghe M, Willekens B, Delvaux V, D'haeseleer M, Guillaume D, Laureys G, Nagels G, Vanderdonckt P, Van Pesch V, Popescu V.
    BMC Neurol; 2021 Jun 22; 21(1):227. PubMed ID: 34157999
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Influence of Previous Failed Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray for Multiple Sclerosis Spasticity.
    Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L.
    Eur Neurol; 2016 Jun 22; 75(5-6):236-43. PubMed ID: 27160412
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis.
    Carod-Artal FJ, Adjamian P, Vila Silván C, Bagul M, Gasperini C.
    Expert Rev Neurother; 2022 Jun 22; 22(6):499-511. PubMed ID: 35582858
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.